Biologically active supplements
search
news
The PDF with the short report with pictures from the therapy of a diabetic foot can be viewed or downloaded here.
The pictures from the treatment of unhealing wounds an be found here:
http://www.onkocet.eu/en/produkty-detail/220/1/
The pictures from the treatment of unhealing wounds an be found here:
http://www.onkocet.eu/en/produkty-detail/293/1/
ONKOCET Ltd. has exhibited the devices from its portfolio on the MEDTEC UK exhibition in Birmingham, April 2011 through our partner Medical & Partners.
The ONKOCET company has successfully reached the certification of yet another medical device, Infrared Camera SVIT. The Certificate can be found here. The videos from the device operation can be found here.
Our device, the non-invasive blood analyzer AMP has won the Golden Incheba prize at a medical exhibition SLOVMEDICA - NON-HANDICAP 2010. A big thank you goes to the organizers of the exhibition for acknowledging the quality of our device and to the exhibitor, the Medical & Partners company, for introduction of the AMP device to the medical public again.We are pleased to inform our business partners, that our company has succesfully finished the certification process of Concor Soft Contact Lenses.
You can find the certificate here.More information on Concor Soft Contact Lenses go to section Medical preparations/Concor soft contact lenses, or follow this link.
Our company has finished the certification process for another medical device, computerized spirometer MAS-1K with oximeter. You can find the device certificate here..jpg)
Since May 2010 there is a new version of AMP device available.Follow this link if you want to see the pictures and specifications of the device.
http://www.onkocet.eu/en/produkty-detail/293/1/
Dear partners, In October 2009 we have received CE certificate for another device from our portfolio, NO therapeutical device PLASON. You can find more information about this revolutionary device, used for healing of unhealing wounds, diabetic foot, or for cosmetical purposes, at our webpage, section "Medical devices" -> PLASON-NO Therapy.
.gif)
Best regards
Team of ONKOCET Ltd. company
Experimental studies and clinical trials of Glymurid and it´s analogues
Experimental data
We have synthesized a number of new glycoside derivatives of MDP. Among them, there were ?- and ?-glycosides of MDP differing by their lipophilicity and structure of their aglycons. We have studied and compared the immunomodulating activities of above derivatives in model test systems in vitro. Amphiphilic analogs with alkyl (4-16 carbon atoms), adamantyl, cycloalkyl (6 carbon atoms), phenyl structure of aglycons have been shown to be more effective stimulators of T and B lymphocyte proliferation and allospecicfic cytotoxic T cell generation in mixed lymphocyte culture, and more effective activators of interleukin-1 and tumor necrosis factor production by murine macrophages in comparison with MDP and its more lipophilic analogues used in equimolar concentration. As a rule, glycoside derivatives with ?-configuration exceeded the effects of ?-glycosides.
These results correlate with high regulatory activities of amphiphilic ?-glycosides of MDP /including ?-heptylglycoside-MDP (GLYMURID) and ?-adamantylglycoside-MDP (MURADAMYL)/ on cellular and humoral immune reactions in model systems in vivo. In mice with genetically low immune reactivity to T cell-dependent antigen (ovalbumin), the preparations increased the indices of both cellular (hypersensitiveness of delayed type) and humoral (antibody formation) reactions caused by this antigen. On the contrary, ?-glycosides of MDP suppressed above reactions in animals with genetically high immune reactivity to ovalbumin. These data allow to consider Glymurid and Muradamyl to be immunomodifiers (or immunomodulators, or immunocorrectors) but not only immunostimulators.
The next sets of experiments revealed significant therapeutic and prophylactic effects of amphiphilic ?-glycosides of MDP in murine models of infectious diseases, including sepsis caused with gram-positive and gram-negative bacteria, as well as in models of lymphoma, melanoma and lung carcinoma. The most active among MDP analogs tested was ?-heptylglycoside-MDP (GLYMURID). It worth mentioning that the above preparation was shown to possess very low toxicity and to be highly effective when used per os.
We guess that ?-configuration of MDP glycoside derivatives improved interaction of the immunomodifier with corresponding cellular (surface or intracellular) receptors of immune cells. Amphiphilicity of muramylpeptides gives them advantages in nonspecifically penetration throw plasma membrane compared to their hydro- and lipophilic analogues. Internalization of MDP analogues into macrophages and other cells of immune system is of a great importance for interaction of the preparations with specific intracellular sites and cell activation.
Clinical trials
Now several ?-glycosides of MDP are extensively studied to enter the stage of clinical trials. One of them, amphiphilic preparation ?-heptylglycoside-MDP in form of biologically active food supplement GLYMURID is successfully used in complex treatment of several diseases accompanied with secondary immune insufficiency.
We have carried several randomized double-blind placebo-controlled clinical studies documented with official reports.
1. Postoperative adjuvant therapy of patients with gastro-intestinal tumors (Regional Clinical Hospital, Tomsk, Russia)
40 patients (45-65 years old) receiving 5-fluoruracyl after radical removal of gastric and colic malignant tumors (T3N0-2M0) were randomized in 2 groups (‘test’ and ‘placebo’). In test-group, Glymurid was administered at a dose of 0.1 mg daily for 2 weeks simultaneously with course of 5-fluoruracyl (15 mg/kg every other day). Patients of placebo-group received capsules of placebo instead of Glymurid at the same schedule. In contrast to placebo-group, Glymurid caused restoration of normal indices of cellular and humoral immunity in peripheral blood, significantly improved clinical and biochemical parameters of liver function, markedly increased life quality estimated with criteria of EORTC (EORTC QLQ CORE 30), prevented an increase of tumor markers (CEA, CA-19-9, CA-72-4), which was observed in placebo-group in 6 and 12 months after surgery (table 1). Side effects have not been revealed. Thus, Glymurid potentiated the results of combined (surgery + chemotherapy) cancer therapy, prevented and corrected hematological and immune disorders as well as liver dysfunction caused by chemotherapeutic drugs.
Hematological, immunological and biochemical indices in patients with removed carcinoma of stomach or colon before and after complex adjuvant therapy (5-fluoruracyl + Glymurid)
2. Chronic opisthorchiasis (Regional Clinical Hospital, Tomsk, Russia)
Glymurid was shown to correct immune disorders in patients with residual opisthorchiasis. Opisthorchis felineus invasion induces marked immune disorders. 40 patients with chronic opisthorchiasis were examined. In these patients, we found a decrease of CD4+ cell number and metabolic activity of neutrophils and an increase of CD19+ cell number and serum content of IgA, IgG, IgM and IgE. Immune abnormalities were accompanied with allergic and infectious complications of the main disease. Immune status had not been improved in most of the patients in 6 months after dehelmintisation with prasiquantel at a course dosage of 60 mg/kg. The patients with residual immune disorders were randomized to receive either Glymurid at a dose of 0.1 mg daily or a placebo. Each group contained 20 patients. All patients were evaluated every day for clinical status and every week for cell blood count, blood chemistry and immune status. 10-day dietary supplementation of muramyl dipeptide derivative caused significant improvement (p<0.05) of such indices of immune system as CD4+ and CD19+ cell count, serum content of immunoglobulins and marked tendency to normalization of other changed indices (Table 2). Immunomodulatory effect of the preparation was stable and continued at least 6 months after Glymurid treatment. No side effects have been revealed.
3. Complex treatment of chronic viral hepatitis C (Kuban State Medical Academy, Krasnodar, Russia)
40 patients with chronic viral hepatitis C were randomized to receive either Glymurid at a dose of 0.1 mg every other day (20 patients) or a placebo (20 patients) for 20 days. Besides, all patients were treated with standard preparations for detoxication and hepatoprotection. In contrast to above 2 studies, Glymurid did not cause marked changes of biochemical and immunological indices, which may be due to significant individual variations of these indices. Nevertheless, we found Glymurid-induced disappearance of viral RNA (more precisely – decrease of quantity of HCV-RNA bellow sensitivity level of PCR method) in peripheral blood in 85% and 65% of cases in 3 weeks and 3 months after treatment finish, respectively (Figure). Side effects have not been revealed. Now we continue observation over these patients and see the absence of hepatitis C virus in peripheral blood in more than 50% of examined patients as estimated in 12 months after finish of Glymurid application. Reported data are really surprising because the best results of permanent 12-months treatment of chronic hepatitis C with interferon-? do not exceed 25-30%. Moreover, in contrast to Glymurid, interferon-? preparations have a great number of contraindications and side toxic effects, which significantly restrict the application of interferon. We consider marked antiviral effect of Glymurid to be due to induction of endogenic synthesis of interferons-? and -? and activation of specific immune reaction against virus and virus-infected cells.